BioPharma

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for...

DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.

Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.